{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.464","value":"1.52"},{"groupId":"OG001","spread":"0.503","value":"2.17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"Nanatinostat (Cycle 1 Day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0","value":"1.21"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Nanatinostat (Cycle 6 Day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.34","value":"3.41"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Ganciclovir (Cycle 1 Day 1)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.36","value":"5.31"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Ganciclovir (Cycle 6 Day 1)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"description":"Defined as the time required to reduce plasma concentration by 50% after study drug administration","dispersionType":"Standard Deviation","groups":[{"description":"Patients with relapsed or refractory EBV-positive lymphoma or lymphoproliferative disorder treated with nanatinostat 20 mg once daily (QD) on Days 1 to 4 per week and valganciclovir 900 mg QD","id":"OG000","title":"Combination Therapy (EBV-Associated Lymphoid Malignancy)"},{"description":"Patients with relapsed or refractory EBV-positive angioimmunoblastic T-cell lymphoma or peripheral T-cell lymphoma not otherwise specified treated with nanatinostat 20 mg QD on Days 1 to 4 per week","id":"OG001","title":"Monotherapy (EBV-Positive Peripheral T-Cell Lymphoma)"}],"paramType":"MEAN","populationDescription":"Defined as all patients who received at least 1 dose of study drug on Cycle 1 Day 1 and had at least 2 valid PK concentrations in the terminal elimination phase. This stricter requirement explains why, for example, the overall number analyzed for t1/2 (ie, 16) is less than the overall number analyzed for the other PK parameters (ie, 50). As prespecified by the analysis plan, combination therapy cohorts were combined since t1/2 for small molecules should not be affected by lymphoma subtype.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 and Cycle 6 Day 1 at pre-dose and 1, 2, 4, and 6 hours post-dose (each cycle was 28 days)","title":"Pharmacokinetic (PK) Parameter - Half-Life [t1/2]","type":"SECONDARY","unitOfMeasure":"hours"}